Lack of somatic mutations in the catalytic domains of CREBBP and EP300 genes implies a role for histone deacetylase inhibition in myeloproliferative neoplasms

Leukemia Research

Volumn 36, Issue 4, 2012, Pages 485-487

  Andersen, Christen Lykkegaard ^a,b   Hasselbalch, Hans ^b   Grønbæk, Kirsten ^a  

^a Mental Health Center Glostrup   (Denmark)

^b ROSKILDE HOSPITAL   (Denmark)

Author keywords

Chronic Ph negative myeloproliferative disorders; CREEBP; EP300; Epigenetic regulation; Histone acetyltransferase (HAT) genes; Histone deacetylase inhibition (HDACi); Histone deacetylases (HDAC); Tyrosine kinases

Indexed keywords

ADENINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DNA; E1A ASSOCIATED P300 PROTEIN; GUANINE; HISTONE DEACETYLASE;

ARTICLE; CARCINOGENESIS; CREBBP GENE; DENATURING GRADIENT GEL ELECTROPHORESIS; DNA PURIFICATION; ENZYME ACTIVE SITE; ENZYME INHIBITION; EP300 GENE; GENE; HUMAN; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; NUCLEIC ACID BASE SUBSTITUTION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SOMATIC MUTATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

BASE SEQUENCE; CATALYTIC DOMAIN; CREB-BINDING PROTEIN; DNA MUTATIONAL ANALYSIS; E1A-ASSOCIATED P300 PROTEIN; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; MYELOPROLIFERATIVE DISORDERS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84857239094     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.11.018     Document Type: Article

References (8)

1. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7(April (4)):387-397.
2. Vannucchi A.M., Biamonte F. Epigenetics and mutations in chronic myeloproliferative neoplasms. Haematologica 2011, 96(October (10)):1398-1402.
3. Morin R.D., Mendez-Lago M., Mungall A.J., Goya R., Mungall K.L., Corbett R.D., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476(August (7360)):298-303.
4. Pasqualucci L., Dominguez-Sola D., Chiarenza A., Fabbri G., Grunn A., Trifonov V., et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471(March (7337)):189-195.
5. Guerini V., Barbui V., Spinelli O., Salvi A., Dellacasa C., Carobbio A., et al. The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F). Leukemia 2008, 22(April (4)):740-747.
6. Rambaldi A., Dellacasa C.M., Finazzi G., Carobbio A., Ferrari M.L., Guglielmelli P., et al. A pilot study of the histone-deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol 2010, 150(August (4)):446-455.
7. Andersen C, Ejerblad E, Zweegman S, Klausen T, McMullin MF, Hasselbalch HC, On Behalf of The COSMYD-Group. A Phase II Study of Vorinostat (MK-0683) in Patients with Polycythemia Vera and Essential Thrombocythaemia. EHA - oral presentation. London; 2011.
8. Guldberg P., Gronbaek K., Worm J., Straten P., Zeuthen J. Mutational analysis of oncogenes and tumor suppressor genes in human cancer using denaturing gradient gel electrophoresis. Methods Mol Med 2002, 68:125-139.